Nanoparticles in drug delivery: From history to therapeutic applications

O Afzal, ASA Altamimi, MS Nadeem, SI Alzarea… - Nanomaterials, 2022‏ - mdpi.com
Current research into the role of engineered nanoparticles in drug delivery systems (DDSs)
for medical purposes has developed numerous fascinating nanocarriers. This paper reviews …

[HTML][HTML] Advances in chitosan-based nanoparticles for drug delivery

V Mikušová, P Mikuš - International journal of molecular sciences, 2021‏ - mdpi.com
Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and
medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug …

[HTML][HTML] On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles

ML Formica, DA Real, ML Picchio, E Catlin… - Applied Materials …, 2022‏ - Elsevier
The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier

D Lee, T Minko - Pharmaceutics, 2021‏ - mdpi.com
Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

[HTML][HTML] Nanotechnology-based drug delivery for central nervous system disorders

TT Nguyen, TTD Nguyen, TK Vo, MK Nguyen… - Biomedicine & …, 2021‏ - Elsevier
Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

Anti-Parkinsonian therapy: strategies for crossing the blood–brain barrier and nano-biological effects of nanomaterials

G Cheng, Y Liu, R Ma, G Cheng, Y Guan, X Chen… - Nano-micro letters, 2022‏ - Springer
Abstract Parkinson's disease (PD), a neurodegenerative disease that shows a high
incidence in older individuals, is becoming increasingly prevalent. Unfortunately, there is no …

Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease

P Saha, H Kathuria, MM Pandey - Journal of Controlled Release, 2023‏ - Elsevier
Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications

K Xu, S Duan, W Wang, Q Ouyang, F Qin… - Wiley …, 2024‏ - Wiley Online Library
The blood–brain barrier presents a key limitation to the administration of therapeutic
molecules for the treatment of brain disease. While drugs administered orally or …

Recent biomedical approaches for chitosan based materials as drug delivery nanocarriers

AT Iacob, FG Lupascu, M Apotrosoaei, IM Vasincu… - Pharmaceutics, 2021‏ - mdpi.com
In recent decades, drug delivery systems (DDSs) based on nanotechnology have been
attracting substantial interest in the pharmaceutical field, especially those developed based …

[HTML][HTML] Access to the CNS: Strategies to overcome the BBB

B Sánchez-Dengra, I González-Álvarez… - International Journal of …, 2023‏ - Elsevier
The blood–brain barrier (BBB) limits the access of substances to the central nervous system
(CNS) which hinders the treatment of pathologies affecting the brain and the spinal cord …